1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholder
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Processes
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
4.5. Analyst View
5. PULMONARY FIBROSIS BIOMARKER MARKET BY TEST TYPE
5.1. Introduction
5.2. Blood Tests
5.2.1. Market Trends and Opportunities
5.2.2. Growth Prospects
5.2.3. C-reactive Protein Testing Kits
5.2.4. Antibody Testing Kits
5.2.4.1. Antinuclear Antibodies (ANA) Test
5.2.4.2. Anti-CCP antibody testing
5.2.5. ESR Tests and CBC
5.3. Imaging Tests
5.3.1. Market Trends and Opportunities
5.3.2. Growth Prospects
5.3.3. X-rays Scans
5.3.4. HRCT Scans
5.4. Lung Biopsy
5.4.1. Market Trends and Opportunities
5.4.2. Growth Prospects
6. PULMONARY FIBROSIS BIOMARKER MARKET BY INDICATION
6.1. Introduction
6.2. Idiopathic pulmonary fibrosis (IPF)
6.2.1. Market Trends and Opportunities
6.2.2. Growth Prospects
6.3. Rheumatoid Arthritis Interstitial Lung Disease (RA-ILD)
6.3.1. Market Trends and Opportunities
6.3.2. Growth Prospects
6.4. Drug-induced pulmonary fibrosis
6.4.1. Market Trends and Opportunities
6.4.2. Growth Prospects
6.5. COVID-19-related pulmonary fibrosis
6.5.1. Market Trends and Opportunities
6.5.2. Growth Prospects
6.6. Pneumoconiosis
6.6.1. Market Trends and Opportunities
6.6.2. Growth Prospects
6.7. Sarcoidosis
6.7.1. Market Trends and Opportunities
6.7.2. Growth Prospects
6.8. Others
6.8.1. Market Trends and Opportunities
6.8.2. Growth Prospects
7. PULMONARY FIBROSIS BIOMARKER MARKET BY END-USER
7.1. Introduction
7.2. Diagnostic Laboratories
7.2.1. Market Trends and Opportunities
7.2.2. Growth Prospects
7.3. Academic and Research Institutes
7.3.1. Market Trends and Opportunities
7.3.2. Growth Prospects
7.4. Hospital Laboratories
7.4.1. Market Trends and Opportunities
7.4.2. Growth Prospects
7.5. Biopharmaceutical Companies
7.5.1. Market Trends and Opportunities
7.5.2. Growth Prospects
7.6. Others
7.6.1. Market Trends and Opportunities
7.6.2. Growth Prospects
8. PULMONARY FIBROSIS BIOMARKER MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. By Test Type
8.2.2. By Indication
8.2.3. By End-User
8.2.4. By Country
8.2.4.1. United States
8.2.4.1.1. Market Trends and Opportunities
8.2.4.1.2. Growth Prospects
8.2.4.2. Canada
8.2.4.2.1. Market Trends and Opportunities
8.2.4.2.2. Growth Prospects
8.2.4.3. Mexico
8.2.4.3.1. Market Trends and Opportunities
8.2.4.3.2. Growth Prospects
8.3. South America
8.3.1. By Test Type
8.3.2. By Indication
8.3.3. By End-User
8.3.4. By Country
8.3.4.1. Brazil
8.3.4.1.1. Market Trends and Opportunities
8.3.4.1.2. Growth Prospects
8.3.4.2. Argentina
8.3.4.2.1. Market Trends and Opportunities
8.3.4.2.2. Growth Prospects
8.3.4.3. Others
8.3.4.3.1. Market Trends and Opportunities
8.3.4.3.2. Growth Prospects
8.4. Europe
8.4.1. By Test Type
8.4.2. By Indication
8.4.3. By End-User
8.4.4. By Country
8.4.4.1. United Kingdom
8.4.4.1.1. Market Trends and Opportunities
8.4.4.1.2. Growth Prospects
8.4.4.2. Germany
8.4.4.2.1. Market Trends and Opportunities
8.4.4.2.2. Growth Prospects
8.4.4.3. France
8.4.4.3.1. Market Trends and Opportunities
8.4.4.3.2. Growth Prospects
8.4.4.4. Italy
8.4.4.4.1. Market Trends and Opportunities
8.4.4.4.2. Growth Prospects
8.4.4.5. Spain
8.4.4.5.1. Market Trends and Opportunities
8.4.4.5.2. Growth Prospects
8.4.4.6. Others
8.4.4.6.1. Market Trends and Opportunities
8.4.4.6.2. Growth Prospects
8.5. Middle East and Africa
8.5.1. By Test Type
8.5.2. By Indication
8.5.3. By End-User
8.5.4. By Country
8.5.4.1. Saudi Arabia
8.5.4.1.1. Market Trends and Opportunities
8.5.4.1.2. Growth Prospects
8.5.4.2. UAE
8.5.4.2.1. Market Trends and Opportunities
8.5.4.2.2. Growth Prospects
8.5.4.3. Others
8.5.4.3.1. Market Trends and Opportunities
8.5.4.3.2. Growth Prospects
8.6. Asia Pacific
8.6.1. By Test Type
8.6.2. By Indication
8.6.3. By End-User
8.6.4. By Country
8.6.4.1. Japan
8.6.4.1.1. Market Trends and Opportunities
8.6.4.1.2. Growth Prospects
8.6.4.2. China
8.6.4.2.1. Market Trends and Opportunities
8.6.4.2.2. Growth Prospects
8.6.4.3. India
8.6.4.3.1. Market Trends and Opportunities
8.6.4.3.2. Growth Prospects
8.6.4.4. South Korea
8.6.4.4.1. Market Trends and Opportunities
8.6.4.4.2. Growth Prospects
8.6.4.5. Taiwan
8.6.4.5.1. Market Trends and Opportunities
8.6.4.5.2. Growth Prospects
8.6.4.6. Thailand
8.6.4.6.1. Market Trends and Opportunities
8.6.4.6.2. Growth Prospects
8.6.4.7. Indonesia
8.6.4.7.1. Market Trends and Opportunities
8.6.4.7.2. Growth Prospects
8.6.4.8. Others
8.6.4.8.1. Market Trends and Opportunities
8.6.4.8.2. Growth Prospects
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Biogen
10.2. Veracyte
10.3. Genentech (Roche)
10.4. Galapagos NV
10.5. Biocartis
10.6. Myriad Genetics